Argenx
ARGX
#402
Rank
C$83.47 B
Marketcap
C$1,327
Share price
-1.73%
Change (1 day)
2.45%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): C$31.50

According to Argenx 's latest financial reports the company's current EPS (TTM) is C$32.06. In 2025 the company made an earnings per share (EPS) of C$30.23 an increase over its 2024 EPS that were of C$19.96.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$31.504.21%
2025C$30.2351.44%
2024C$19.96-369.77%
2023C-$7.40-60.46%
2022C-$18.7163.33%
2021C-$11.46-40.37%
2020C-$19.22183.47%
2019C-$6.78123.09%
2018C-$3.0454.93%
2017C-$1.9614.07%
2016C-$1.7213.05%
2015C-$1.52-36.34%
2014C-$2.39209.04%
2013C-$0.77-33.99%
2012C-$1.17185.59%
2011C-$0.41